Stock Track | Humacyte Shares Soar on Positive Analyst Ratings and Outlook

Stock Track

Oct 18, 2024

Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.

Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a "Buy" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.

Piper Sandler analyst Allison Bratzel also weighed in, maintaining a "Hold" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113068705"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113068705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113068705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113068705","market":"us","top_or_hot":-1,"title":"Stock Track | Humacyte Shares Soar on Positive Analyst Ratings and Outlook","media":"Stock Track","content":"<p>Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.</p>\n\n<p>Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a \"Buy\" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.</p>\n\n<p>Piper Sandler analyst Allison Bratzel also weighed in, maintaining a \"Hold\" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Humacyte Shares Soar on Positive Analyst Ratings and Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Humacyte Shares Soar on Positive Analyst Ratings and Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-18 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.</p>\n\n<p>Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a \"Buy\" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.</p>\n\n<p>Piper Sandler analyst Allison Bratzel also weighed in, maintaining a \"Hold\" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUMA","symbol_name":"Humacyte, Inc.","start_time":0,"source_url":"","article_id":"1113068705","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113068705","pubTimestamp":1729258596,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Humacyte, Inc.  surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a \"Buy\" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUMA":"Humacyte, Inc."},"translate_title":"股票跟踪Humacyte股价因分析师评级和前景积极而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1},"content_text":"Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.\nLeading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a \"Buy\" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.\nPiper Sandler analyst Allison Bratzel also weighed in, maintaining a \"Hold\" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}